KR102590647B1 - Composition for preventing, improving or treating obesity comprising fermented product of Momordica charantia or compound isolated therefrom as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, improving or treating obesity containing a fermented bitter melon or a compound isolated therefrom as an active ingredient. The fermented bitter melon or a new compound isolated therefrom of the present invention has an excellent ability to inhibit fat accumulation. Therefore, it can be useful as a material for anti-obesity health functional food or obesity treatment.

Description

Composition for preventing, improving or treating obesity comprising fermented product of Momordica charantia or compound isolated therefrom as effective component}

The present invention relates to a composition for preventing, improving or treating obesity containing fermented bitter melon or a compound isolated therefrom as an active ingredient.

Obesity is a condition in which excessive adipose tissue is accumulated in the body. It is mainly induced by energy imbalance that occurs when nutrient intake is excessive compared to energy consumption. In addition, it can also be caused by hormonal changes, genetics, mental health problems, and socioeconomic factors. It is known to be induced. The obese population is increasing worldwide, and the severity of obesity has recently emerged as an important issue as it has been pointed out as an important factor causing adult diseases.

Current treatments for obesity include fenfluramine, which inhibits the serotonergic nervous system, ephedrine and caffeine, which act on the noradrenergic nervous system, sibutramine, which acts simultaneously on the serotonin and noradrenergic nervous system, and Orly, which reduces fat absorption by inhibiting lipase produced in the pancreas. There are medications such as Start. However, among the previously used drugs, fenfluramine has been banned due to side effects such as primary pulmonary hypertension and heart valve lesions, and other drugs have also caused problems such as decreased blood pressure and lactic acidemia, so they are not used in patients with heart failure or renal disease. There is a problem that cannot be done. Therefore, the development of substances to prevent, improve, or treat obesity with fewer side effects is required.

Meanwhile, Korea Patent Publication No. 2010-0134575 discloses the use of compounds extracted from bitter melon in the manufacture of drugs for preventing and treating diabetes and obesity, and Korean Patent No. 1690369 discloses the use of mixed hot water extracts of bitter melon as an active ingredient. 'A pharmaceutical composition for anti-obesity and a method for producing the same' is disclosed, but there is no description of a composition for the prevention, improvement or treatment of obesity containing the fermented product of bitter melon of the present invention or a compound isolated therefrom as an active ingredient. .

The present invention was developed in response to the above-mentioned needs, and the present inventors have discovered that the compound of formula 1 isolated from the fermented bitter melon fruit and the fraction of the fermented bitter melon fermented by adding the filtrate of crushed button mushroom to the bitter melon hot water extract is 3T3-L1. The present invention was completed by confirming that it had excellent ability to inhibit fat accumulation in preadipocytes.

In order to solve the above problems, the present invention provides a compound of Formula 1 or an acceptable salt thereof; Or a fermented bitter melon containing the compound of Chemical Formula 1; provided as a health functional food composition for preventing or improving obesity containing as an active ingredient.

Additionally, the present invention relates to a compound of Formula 1 or an acceptable salt thereof; Or a fermented bitter melon containing the compound of Formula 1; Provided is a pharmaceutical composition for preventing or treating obesity containing as an active ingredient.

The fermented bitter melon of the present invention or the new compound isolated therefrom has an excellent ability to inhibit fat accumulation, so it is expected to be useful as a material for anti-obesity health functional food or obesity treatment.

Figure 1A shows the results of HPLC (High Performance Liquid Chromatography) on Yeoju hot water extract and the ethyl acetate fraction (EtOAc) of Yeoju fermented product, and Figure 1B shows the APM-1 compound (chemical formula) isolated from the ethyl acetate fraction of Yeoju fermented product. 1) and the structural formula of APM-2 compound (Formula 2). Red arrows: APM-1 compound (t _R 9.2 min) and APM-2 compound (t _R 11.6 min) isolated from the EtOAc fraction.
Figure 2 shows Yeoju hot water extract, Yeoju fermented product, fractions of Yeoju fermented product (n-Hexane layer, EtOAc layer, n-BuOH layer, HO layer), and APM-1 compound (Formula 1) or APM-2 compound separated therefrom. This is a result of confirming the cytotoxicity of (Formula 2).
Figure 3A shows the results of confirming the fat accumulation inhibition ability of bitter melon hot water extract, bitter melon fermentation, or fractions of bitter melon fermentation (n-Hexane layer, EtOAc layer, n-BuOH layer, H2O layer), and Figure 3B shows the ethyl acetate fraction of bitter melon fermentation. This is the result of confirming the fat accumulation inhibition ability of A PM-1 compound (Formula 1) and APM-2 compound (Formula 2) isolated from (EtOAc). DMI: adipogenesis-promoting inducer (1μM Dexamethasone, 0.5mM IBMX, 1μM Insulin), Nor: DMI untreated group (sample untreated). Cont: DMI treated group (no sample treatment), EGCG (positive control): (-)-epigallocatechin gallate.
Figure 4 is a photograph of Oil red O staining results of 3T3-L1 preadipocytes treated with APM-1 compound (Formula 1). DMI: adipogenic inducer (1μM Dexamethasone, 0.5mM IBMX, 1μM Insulin).

In order to achieve the object of the present invention, the present invention is a compound of the following formula (1) or an acceptable salt thereof; Or, it provides a health functional food composition for preventing or improving obesity containing as an active ingredient a fermented bitter melon containing a compound of the following formula (1).

In the health functional food composition of the present invention, the compound of formula 1 may be separated from the fermented bitter melon, preferably separated from the ethyl acetate fraction (EtOA) of the fermented bitter melon. It is not limited, and it is possible to extract or synthesize it from other natural products.

In the health functional food composition of the present invention, the fermented product of bitter melon may be obtained by fermenting bitter melon hot water extract with button mushroom ( Agaricus bisporus ) mycelium, but is not limited thereto. The button mushroom mycelium may refer to a filtrate obtained by filtering a mixture of crushed button mushrooms and distilled water, and the filtrate contains polyphenol oxidase.

The fermented bitter melon of the present invention, its fractions, or compounds isolated therefrom have an excellent ability to inhibit fat accumulation in 3T3-L1 preadipocytes and are effective in improving obesity.

As used herein, the term “acceptable salt thereof” refers to any salt of the present compound that retains the biological properties of the present compound and is not toxic or unsuitable for pharmaceutical use. Such salts may be derived from and include a variety of organic and inorganic counterions known in the art. These salts include organic or inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, Pyruvic acid, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, chric acid, cinnamic acid, mandelic acid, phthalic acid, Lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzene sulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphoric acid, camphor acid. Forsulfonic acid, 4-methylbicyclo [2.2.2]-oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid. , acid addition salts formed with glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, cyclohexylsulfamic acid, quinic acid or muconic acid, etc.; or the acidic proton present in the parent compound is a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion), an alkali metal, or an alkaline earth metal hydroxide (e.g., sodium, potassium, calcium, magnesium, aluminum, lithium, zinc). and barium hydroxide), ammonia, or substituted with an organic base such as aliphatic, cycloaliphatic or aromatic organic amines such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanol. Amine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine , tris(hydroxymethyl)-aminomethane, or a salt formed when coordinated with tetramethylammonium hydroxide.

Additionally, examples of salts include sodium, potassium, calcium, magnesium, ammonium, or tetraalkylammonium salts, and when the compound contains a basic functional group, salts with non-toxic organic acids or inorganic acids, such as hydrohalides (e.g., hydrohalides). chloride or hydrobromide), sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, lutein Bates, lactate, malonate, succinate, sorbate, ascorbate, maleate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl fumarate, tartarate) citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane -Disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4- Methylbicyclo[2.2.2]-oct-2-en-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethyl acetate, tert-butylacetate, lauryl sulfate, gluconate, benzoate. It may include ate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, or muconate salt.

The health functional food composition of the present invention may be in a formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.

When using the compound of the present invention or a fermented bitter melon containing the compound as a food additive, the compound of the present invention or a fermented bitter melon containing the compound may be added as is or used together with other foods or food ingredients, It can be used appropriately according to conventional methods. The mixed amount of active ingredients can be appropriately used depending on the purpose of use (prevention or improvement). Generally, when manufacturing a food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for health purposes, the amount may be below the above range.

There are no special restrictions on the types of foods above. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. There are drinks, alcoholic beverages, and vitamin complexes, and it includes all health foods in the conventional sense. The beverages include carbonated beverages, functional ion beverages, juices (e.g., apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), sikhye, and the like.

The functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufacturing a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., , xylitol, sorbitol, erythritol, etc.) are preferred. The flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.). In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonated drinks. It may further contain a carbonating agent used for.

In addition to the above health functional food composition, various nutrients, vitamins, inhibitors, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may further contain carbonating agents used in carbonated drinks. The ratio of the ingredients added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.

The present invention also provides a compound of Formula 1 or an acceptable salt thereof; Or it provides a pharmaceutical composition for the prevention or treatment of obesity containing as an active ingredient a fermented bitter melon containing the compound of Formula 1.

In the pharmaceutical composition of the present invention, the compound of Formula 1 is isolated from a fraction of the fermented bitter melon, and the fermented bitter melon or the compound isolated therefrom is as described above.

The pharmaceutical composition according to the present invention can be formulated and used in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. You can.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to the active ingredient, and such carriers are commonly used in formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, Calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals. Includes, but is not limited to, oil. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. When adding the above ingredients, skin safety due to combined use, ease of formulation, and stability of the active ingredients can be taken into consideration.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, and activity of the patient's disease. , may be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the field of medicine. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically on the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.

Hereinafter, the present invention will be described in detail by examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.

Preparation Example 1. Preparation of Yeoju fermented product

4.5 kg of dried Yeoju purchased from Duson Ae Herb Co., Ltd. was immersed in 45 L of water, extracted at 90°C for 3 hours, and then concentrated under low temperature and reduced pressure to obtain 1.5 kg of Yeoju hot water extract concentrate. In addition, for the enzymatic reaction of Yeoju hot water extract, 40 g of button mushroom ( Agaricus bisporus ) was mixed with 100 ml of distilled water, pulverized in a blender, and filtered through 5-layer gauze to prepare an enzyme source containing polyphenol oxidase. . To measure the polyphenol oxidase activity of the prepared enzyme source (60 ml), the content of benzotropolone produced after the oxidation reaction was measured using a UV spectrophotometer at 360 nm using pyrogallol as a substrate. The absorbance was measured, and an enzyme source with an absorbance value of 0.78 to 0.79 was used for the enzyme reaction of the Yeoju hot water extract. Absorbance was measured after placing 1.5 ml of enzyme source in a quartz cell with 1.5 ml of 200 mM pyrogallol (in 50 mM sodium phosphate buffer, pH 7.2) and inducing an oxidation reaction for 5 minutes. The Blank group was given 1.5 ml of substrate solution. and 1.5 ml of distilled water were added (see Food Chemistry, 88, 2004, 69-77 and BBRC, 130(2), 1985, 633-639).

Next, 15 g of Yeoju hot water extract concentrate was diluted in 40 ml of distilled water, placed in a 500 ml beaker along with 60 ml of enzyme source, and reacted at room temperature for 80 minutes using a stirrer to prepare Yeoju fermented product.

Example 1. Isolation of compounds of formulas 1 and 2 from bitter melon fermentation product

The enzyme reaction experiment of bitter melon was repeated 36 times, and 750 g of the fermented bitter melon produced was diluted in 2 liters of 10% methanol (MeOH) and mixed with n-hexane (2 liters x 3 times), ethyl acetate (EtOAc, After fractionation and extraction using n-butanol (BuOH, 2 ℓ×3 times) and n-butanol (BuOH, 2 ℓ×3 times), the fractions for each solvent above were concentrated under reduced pressure at low temperature and dried to obtain 0.2 g of n-hexane fraction, 3.3 g of EtOAc fraction, 17.4 g of n-BuOH fraction and 540.9 g of H ₂ O fraction were obtained.

Next, it has an excellent ability to inhibit the differentiation of 3T3-L1 preadipocytes. 2.3 g of the soluble portion of the EtOAc fraction was subjected to column chromatography using a Toyopearl HW-40 column (2.5 cm id × 42 cm) while increasing the MeOH content of H ₂ O/MeOH to obtain subfractions EMC01 to EMC06. APM-1 (t _R 9.2 min, 16.3 mg) and APM-2 were obtained from 171.4 mg of small fraction EMC02 by performing column chromatography using YMC Pack ODS A-302 column (4.6 cm id (t _R 11.6 min, 19.7 mg) compound was obtained (Figure 1A). The mobile phase used was 0.1% formic acid (solvent A) and acetonitrile (solvent B), and gradient elution was analyzed with 100% solvent A for 30 min, 0% A; The material was analyzed with a solvent composition of 100% B, and the flow rate of the mobile phase was maintained at 1.0 mL/min to detect the compound at 280 nm (Table 1).

Example 2. Structure determination of compounds of formula 1 and 2 isolated from fermented bitter melon

The compounds isolated from the ethyl acetate fraction of the fermented bitter melon were determined to be a new compound represented by Formula 1 and a Monaspilosuslin compound represented by Formula 2 through spectrochemical and structural analysis (Figure 1B).

2-1. Formula 1 (New)

Compound 1 was obtained in the form of a yellow amorphous powder, and showed maximum absorbance at 227 and 291 nm in the UV spectrum, suggesting that it was a γ-lactone skeleton. The molecular weight was estimated by checking the base peak of m/z 143.0344 [M+H] ⁺ in the HRFABMS spectrum, and the molecular formula was confirmed to be C ₆ H ₇ O ₄ . In the 1H NMR spectrum, a proton signal corresponding to one double bond was observed at δ 7.91 (1H, s, H-6), and one methyl group was observed at δ 2.27 (3H, s, H-7). In the ¹³ C NMR and HSQC spectra, one carbonyl carbon signal was observed at δ 168.5 (C-2), and one methyl group along with five double bond carbon signals were observed at δ 13.8 (C-7). In the key HMBC spectrum, H-6 showed correlation with C-4 and 5, and H-7 showed HMBC correlation with C-2, 3, and 4. As a result of the above results, Compound 1 was confirmed to be a new compound that had not previously been reported, and its structure was determined as a tetronic acid derivative compound.

2-2. Formula 2 (Monaspilosuslin)

Compound 2 was obtained in the form of a brown amorphous powder, and the molecular weight was estimated by confirming the base peak of m/z 323 [M+Na] ⁺ as a result of FABMS measurement. In the ¹ H NMR spectrum, signals corresponding to trans -olefin were measured at δ 7.85 (1H, d, J = 15.6 Hz, H-8) and 6.23 (1H, d, J = 15.6 Hz, H-7). A singlet proton corresponding to a double bond was observed at δ 5.77 (1H, s, H-10). Also, one oxygenated methine δ 4.09 (1H, m, H-3), one hydroxymethyl group δ 3.70 (1H, d, J = 7.2 Hz, H-13), 3.63 (1H, d, J = 7.2 Hz, H -13), two methylene groups δ 2.00 (1H, m, H-2), 1.80 (1H, m, H-4), 1.78 (1H, m, H-2), 1.77 (1H, m, H- 4) was observed, and three methyl groups were observed at δ 1.96 (3H, s, H-14), 1.08 (3H, s, H-12), and 0.86 (3H, s, H-11). In ¹³ C NMR and HSQC spectra, one carbonyl group was observed at δ 173.3 (C-15), and signals such as trans -olefin, oxygenated methine, hydroxymethyl, and methyl were observed. As a result of 2D NMR measurements of ¹ H- ¹ H COSY, HMBC, and NOESY, the structure of compound 2 was determined to be monaspilosuslin, a sequiterpene compound isolated from rice fermented using Monascus pilosus microorganisms.

Example 3. Confirmation of cytotoxicity

3T3-L1 preadipocytes (Korean Cell Line Bank) were grown in DMEM (Dulbeccos's Modified Eagle's Medium, Gibco, USA) supplemented with 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin (100 U/ml). It was subcultured by adapting it to an incubator at 37°C and 5% CO ₂ . After dispensing the cultured 3T3-L1 cells (1×10 ⁵ cells/well) into a 96-well plate, samples (Yeoju hot water extract, bitter melon fermentation, fractions of bitter melon fermentation, or compounds isolated therefrom) were added at a concentration of 0.02. After treatment and culture, 0.02 ml of MTT solution (5 mg/ml) was added to react. After the reaction was completed, the absorbance was measured at 540 nm using an ELISA plate reader (Tecan Austria GmBH, Grodig, Austria).

As a result, the fermented bitter melon, fractions of the fermented bitter melon, or compounds isolated therefrom all showed a high survival rate of more than 90% (Figure 2), which shows that the fermented bitter melon of the present invention, the fractions of the fermented bitter melon, or the compounds isolated therefrom It was found that there was no cytotoxicity.

Example 4. Confirmation of anti-obesity efficacy

3T3-L1 cells (1×10 ⁵ cells/well) were dispensed onto the plate and cultured for an additional 2 days until each well was 100% filled with cells. The cultured cells were treated with 10% FBS (fetal bovine serum) DMEM medium (Dulbeccos's Modified Eagle's Medium, Gibco, USA) containing DMI (1μM Dexamethasone, 0.5mM IBMX, 1μM Insulin) for adipocyte differentiation for 2 days. After induction, the cells were cultured for 2 days in 10% FBS DMEM containing 2 μM insulin. Afterwards, the culture medium was replaced with 10% FBS DMEM at 2-day intervals for a total of 4 days. Samples were treated with culture medium while inducing adipocyte differentiation. To confirm the degree of fat accumulation on day 8, when differentiation was completed, Oil Red-O staining was performed using a triglyceride assay kit (Sigma-Aldrich, USA), and the stained fat cells were analyzed under an Olympus microscope (Olympus Optical Co. ., Ltd., Japan) was used to observe.

First, as a result of measuring the degree of fat accumulation in fermented bitter melon and its fractions, the group treated only with DMI, an inducer for promoting lipogenesis (Cont, sample untreated), had a lower degree of fat accumulation compared to the untreated control group (DMI and sample untreated). However, it was confirmed that the degree of fat accumulation decreased when DMI and fermented bitter melon or its EtOAc fraction were treated in parallel. In particular, when treated with the EtOAc fraction at a concentration of 20 μg/ml, fat accumulation was suppressed by about 46%, showing a similar effect on suppressing fat accumulation as the positive control group (EGCG treatment) (Figure 3A).

In addition, as a result of measuring the degree of fat accumulation of APM-1 and APM-2 compounds isolated from the ethyl acetate fraction of fermented bitter melon, the degree of fat accumulation was reduced when DMI and APM-1 compounds were treated in parallel, especially at a concentration of 10 uM. When treated with APM-1, fat accumulation was suppressed by about 60%, confirming that the effect of suppressing fat accumulation was superior to that of the positive control group. On the other hand, it was confirmed that the APM-2 compound had little effect on suppressing fat accumulation (Figure 3B).

In addition, to confirm the effect of the APM-1 compound on fat accumulation in differentiated 3T3-L1 cells, Oil red O staining was performed and observed under a microscope. As a result, the APM-1 compound and DMI compared to the DMI treatment group alone. In the experimental group treated in parallel, less red staining was observed (Figure 4). Through this, it was expected that the fermented bitter melon of the present invention, the fraction of the fermented bitter melon, or the compound of formula 1 isolated therefrom could inhibit fat accumulation and thus be effective in improving obesity.

Claims (5)

A health functional food composition for preventing or improving obesity containing a compound of the following formula (1) or an acceptable salt thereof as an active ingredient.
[Formula 1]
delete The health functional food composition for preventing or improving obesity according to claim 1, wherein the health functional food composition is manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage. . A pharmaceutical composition for preventing or treating obesity containing a compound of the following formula (1) or an acceptable salt thereof as an active ingredient.
[Formula 1]
The pharmaceutical composition for preventing or treating obesity according to claim 4, further comprising a carrier in addition to the active ingredient.